Jay Mei

Founder, Chairman & CEO, Antengene Corporation

Dr. Jay Mei, founder,chairman and chief executive officer of Antengene, previously served as a Global Clinical Lead at Celgene Corporation. Dr. Mei has over 25 years of experience in the clinical development of oncology therapeutics globally and successfully led the development of multiple oncology products, including REVLIMID in China, which received NDA approval in China and launched in 2013. Outside of the China market, Dr. Mei was responsible for the clinical trials of REVLIMID, IDHIFA, etc., in more than 30 countries.

Prior to joining Celgene in 2008, Dr. Mei served in multiple global clinical development roles at Novartis Oncology and J&J Pharmaceutical Research & Development. Dr. Mei spent eight years on cancer research at the U.S. National Cancer Institute (NCI) after medical and Ph.D. education. Dr. Mei is an author of over 70 publications and holds multiple patents.

Mark J. Alles

Former Chairman and CEO of Celgene

Mr. Mark J. Alles is the former Chairman and Chief Executive Officer of Celgene Corporation, now a subsidiary of Bristol-Myers Squibb Company (BMS). In his 16-year tenure at Celgene, Mark led the expansion of the company into a global enterprise serving patients with blood cancers, solid tumor cancers and inflammatory diseases. He held a series of commercial and leadership roles of escalating responsibility, consistently delivering industry-leading financial performance. He led teams that completed several multibillion-dollar company and product acquisitions, built a diverse suite of globally marketed medicines and a high potential pipeline of therapeutics for the treatment of cancer, all of which led to the recently completed $74 billion-dollar acquisition of Celgene by BMS. His career spans more than three decades, with a distinguished record of driving medical innovation for patients worldwide.

In addition to his role as Chairman and CEO at Celgene, Mr. Alles served in various leadership roles during his 32-year industry career, including Vice President of the U.S. Oncology business unit at Aventis Pharmaceuticals and other senior commercial management roles at Aventis (Rhône-Poulenc Rorer). He began his career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson.

Eitan Liu

Vice President, Business Operation and Corporate Finance, Antengene Corporation

Mr. Liu is a founding team member of Antengene Corporation. He is currently in charge of business operation and corporate finance at Antengene. Before joining Antengene founding team, Mr. Liu served at CITIC Industrial Investment Group as Investment Director and General Manager of Corporate Strategy and Business Development. He helped CITIC set up and incubate a CITIC senior living company. Mr. Liu also served in various capacities at CBRE, Frost & Sullivan, and Agilent as R&D Engineer, Consultant, Investment Banking, management and etc.

Mr. Liu received his Master’s degree from The Hong Kong University of Science and Technology in engineering and bachelor degree from Harbin Institute of Technology.

Jeff Li

Early Team Member, Antengene Corporation

Mr. Jeff Li is an angel investor and early team member of Antengene Corporation. Before his angel investor career, Mr. Li served at CITIC Industrial Investment Group as Investment Director and Deutsche Bank as Quantitative trader.

Mr. Li received his master and bachelor degree from The Australian National University in Actuarial Science, and Economics.

William Hu

Managing Partner, Qiming Venture Partners

Mr. Hu is a Managing Partner of Qiming Venture Partners. Mr. Hu co-leads Qiming’s practice in the healthcare sector and has been closely involved with more than 20 new ventures, some of which have become public or billion dollar market cap companies. On behalf of Qiming, he invested in Antengene, Tigermed, BBI Lifescience, Tellgen, AmoyDx, APT Medical, Sanyou Orthopedic, Vinno Medical, Aohua Medical, Microtech Medical, Rendu Bio, ET Healthcare, Canbridge, Ark Bio, Connect Pharma, WeDoctor, Medsci, Arrail Dental, Bang'Er orthopedics Hospitals, ShuLan Hospital, Centreherbs, etc.

Formerly, Mr. Hu served as a strategy consultant at IBM BCS, and Marketing & Sales management consultant at several pharmaceutical companies.

Mr. Hu holds a Bachelor of Medicine from Shanghai Medical University and MBA from ENPC SH Campus.

Jason Li

Partner, FountainVest Partner

Mr. Jason Li is a managing director of FountainVest Partners. Mr. Li joined FountainVest in 2008 and has extensive experience in large buyout and cross-board transactions. He now leads the FountainVest’s healthcare practices, and has invested in Antengene Corporation, Chaoju Ophthalmology and other healthcare portfolios.

Formerly, Mr. Li served as a senior associate in Temasek Holdings and as a marketing executive in AIG Group.

Mr. Li holds a Bachelor of Law and Master of Economics from Fudan University, and EMBA from CEIBS.

Yanling Cao

Partner, Boyu Capital

Mr. Cao is a founding member and Partner of Boyu Capital. Mr. Cao has been in charge of investments and portfolio management in the healthcare sector since 2011. He currently serves on the boards of a number of leading pharmaceutical, diagnostic and healthcare service companies.

Prior to Boyu, Mr. Cao worked as an investment professional at General Atlantic and Goldman Sachs on a wide range of strategic and financial transactions. Mr. Cao received Bachelor of Arts in Economics and Mathematics, summa cum laude, from Middlebury College.

Ming Li

Board Member, Managing Partner of TF Capital

Dr. Li has over 10 years experience in pharmaceutical R&D, business consulting and venture capital investment.

He is a seasoned investment expert with strong capital market experience, proven track record in investing healthcare industry, especially bio-tech.

Dr. Li played active roles in constantly creating value by working closely with portfolio companies to develop and achieve strategic and financial goals, attract talents and establish responsible corporate governance.

Dr. Li got PhD in Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Post-doc training in Univ. Toulouse Ill and Univ. Paris VI, France.